Brought to you by 
Gilead and Novo Nordisk sign trial collaboration for NASH combo therapy
18 Mar 2021
Executive Summary
Gilead Sciences Inc. and Novo Nordisk AS signed a trial agreement to study a triple combination therapy for nonalcoholic steatohepatitis (NASH).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- Trial Collaborations
- R&D (No Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement